Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial.
Tchekmedyian V, Dunn L, Sherman E, Baxi SS, Grewal RK, Larson SM, Pentlow KS, Haque S, Tuttle RM, Sabra MM, Fish S, Boucai L, Walters J, Ghossein RA, Seshan VE, Knauf JA, Pfister DG, Fagin JA, Ho AL.
Tchekmedyian V, et al. Among authors: sabra mm.
Thyroid. 2022 Mar;32(3):273-282. doi: 10.1089/thy.2021.0565.
Thyroid. 2022.
PMID: 35045748
Free PMC article.
Clinical Trial.